Foto del docente

Silvia Bordoni

Professoressa associata confermata

Dipartimento di Chimica Industriale "Toso Montanari"

Settore scientifico disciplinare: CHIM/03 CHIMICA GENERALE E INORGANICA

Didattica

Argomenti di tesi proposti dal docente.

DESIGN  AND INVESTIGATION ON THE CHEMISTRY AND DFT THEORETICAL INSIGHTS ON NOVEL COMPOUNDS OF Ru(II) AND MIXED Ru(II)-Au(I) SPECIES BEARING BIOACTIVE MOLECULES WITH POTENTIAL ANTINEOPLASTIC ACTIVITY

The main point is the development and validation of technologies with methods that make possible to face challenges in a modern medicine vision. To date, there are several factors that lead to disability, morbility or mortality, reduction of years of life, due to diseases developed in adulthood, including cancer. The implementation of new therapies is a challenge that Health Care Institutions will need to face to achieve one of the objectives of the OMS, aiming to reduce early mortality, due to non-communicable diseases within 2025. New therapeutic targets, which consider as innovative drugs the molecular feature of the patient's individual pathologies, must be first identified and characterized thus the holistic information will be used to promote various applications into the personalized therapies. Further, climate change with the increasing exposure to cancerogenic agents has a greater health impact by enhancing cancer risk factors, due to extreme events to promote fast human being changing or by hindering the Care Access.

The research will be focused, on the implications that Ru(II) and Au(I) complexes with chelate bioactive molecules could have on innovative medicine. The aim is to design and discover novel organometallic compounds as potential remedies to improve patient lives for the near future.

Main investigations focus on Au(I) and Ru(II) species, acting as antitumoral agents and drug transporters. Furthermore the incorporation of a Au-fragment, commonly very active as antineoplastic agent, into the Ru(II) metal skeleton may induce cooperative or synergistic features, potentially enhancing anticancer properties. The research will be focused on developing a targeted therapy, with improved delivery and effectiveness, along with antitumor structure-activity behavior and the proposed plausible mechanistic paths. The reactions are going to be optimized, from the point of view of reaction conditions to minimize energy expenditure and running experimental procedures by greener means.

Results of the research could lead to new therapies that may relocate care from hospitals to pharmacies and to individual patient homes, by a top-down vision, encouraging further personalized and specific medications.